Genocea Biosciences Inc (GNCAQ)

[kiy]

GNCA....Genocea Biosciences, is this a gift from the StockGODS? A $6 stock going to $24...?...this is SPECULATION until "real" news happens...

GNCA (T/$12-40) ....THIS IS A $6 STOCK today...Cowen analyst Phil Nadeau is out with a bullish note on shares of Genocea Biosciences Inc (NASDAQ:GNCA), reiterating an Outperform rating with a $40 price target, which implies an upside of 586% from current levels.
(IF you can get a good entry price...you will have plenty of opportunity to play this and accumulate shares...just remember that there is no such thing as a sure thing...this is a game so play it like a game until the news becomes real with FDA approval...until then its HYPE...Swing Trade the hell out of it...buy low sell high...)...for now its a $6 stock that has $10 on its mind (...0r does it...?...)...I like seeing how price acts at $4-5-6 and at $9-10-11...this is the life blood of a Swing Trader...the game should be fun...don't sale the farm...this is SPECULATION until "real" news happens...

Genocea Biosciences, lead product candidate is GEN-003, a therapeutic vaccine or immunotherapy that is in Phase 2 trial for the treatment of genital herpes infections. The company is also developing GEN-009, which is in pre-clinical stage for the treatment of immuno-oncology-neoantigen; and GEN-007 that is in research stage for the treatment of Epstein-Barr virus.
https://finance.yahoo.com/news/cowen-sings-praises-genocea-biosciences-211052793.html The reason? Genocea announced data from GEN-003 Phase 2b trial in HSV2 demonstrating significant reductions in several measures of genital lesions through 12 months. Nadeau commented, "We are optimistic that GEN-003 will succeed in Phase III, and think that it addresses a significant commercial opportunity. The CDC estimates that 16% of the U.S. population aged >14 has been infected with HSV-2 and that 20-25% of infected people are aware of their status. This implies that GEN-003 could address a market oppy of 8MM - 11MM people in the U.S. alone. Assuming a price of $300 per course, GEN-003's total addressable market would be $2B+."

(07/24) All the 5 analysts polled in the past 12 months rate Genocea stock a Buy. With a return potential of 323%, the stock's consensus target price stands at $24.67.
Enjoy...Good Trades...


Daily chart has price overbought...I need to know how to act at the $6 level...
60 minute...chart is on a sell right now...

http://stockcharts.com/c-sc/sc?s=GNCA&p=60&yr=0&mn=1&dy=0&i=p75206172804&a=536436369&r=1501033987498